Sanofi Says Genzyme Integration Is On Track, But Fabrazyme Production Won't Meet Goals

Full production of the rare disease drug is pushed back a quarter, but analysts warm to Sanofi's full-year guidance and ability to meet overall goals for R&D and Genzyme integration.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet